Project Aims

DARTBAC will, from a material perspective, develop new antimicrobial technologies that are not based on antibiotics to target infection prevention and eradication on implant surfaces, in hard tissues and in soft tissues. In this way, we are unique yet synergistic with most other initiatives that focus on an antibiotics approach. 
Collectively, we are bringing the entire knowledge-chain regarding development of new material
technologies to combat AMR.

DARTBAC will develop a new workflow based on AOPs of predictive in vitro and in vivo models to test safety and efficacy of newly developed antimicrobial technology in order to shorten the time to market. DARTBAC will enhance the therapeutic efficacy of current antibiotics by combination therapy and we will develop and validate these technologies so that they can be brought to the market within the project timeframe.
Finally, we will maintain awareness of the emerging AMR problem in the Netherlands by informing the general public and HealthCare Practitioners (HCPs). This increased AMR awareness by HCPs, the general public, and healthcare policy makers can speed up acceptance and market introduction of these technologies both nationally and internationally. Moreover, such acceptance will ensure that insurance providers and advisory bodies adopt and reimburse new treatment approaches quicker, thereby accelerating clinical implementation.

A successful DARTBAC project with the combination of these goals and objectives can prevent a rise in infection percentage due to AMR, minimize the effect of AMR in the Netherlands, and work towards a Dutch society that is less dependent on antibiotic therapy for infection, prevention, and treatment.

DARTBAC will

  • From a material perspective, develop new antimicrobial technologies that are not based on antibiotics to target infection prevention and eradication on implant surfaces, in hard tissues, and in soft tissues.
  • Assess safety and efficacy of these newly developed antimicrobial technologies.
  • Enhance the therapeutic efficacy of current antibiotics by combination therapy.
  • Develop a new workflow based on AOPs (adverse outcome pathways) of predictive in vitro and in vivo models to test safety and efficacy of newly developed antimicrobial technology in order to shorten the time to market.
  • Maintain awareness of the emerging AMR problem in the Netherlands by informing the general public and HCPs.

Project aims

What are our project goals?

DARTBAC will, from a material perspective, develop new antimicrobial technologies that are not based on antibiotics to target infection prevention.

Create societal AMR awareness

Develop new antimicrobial technologies

Optimize AB efficacy with combination therapy

Standardize testmodels for faster clinical implementation

Menu